Tocilizumab and soluble interleukin-6 receptor in JAK2 V617F somatic mutation and myeloproliferative neoplasm

Kasper Mønsted Pedersen; Yunus Çolak; Hans Carl Hasselbalch; Stig Egil Bojesen; Børge Grønne Nordestgaard

doi:10.1016/j.eclinm.2020.100337

Tocilizumab and soluble interleukin-6 receptor in JAK2 V617F somatic mutation and myeloproliferative neoplasm

EClinicalMedicine. 2020 May 3:22:100337. doi: 10.1016/j.eclinm.2020.100337. eCollection 2020 May.

Authors

Kasper Mønsted Pedersen^{1

2

3}, Yunus Çolak^{1

2

3}, Hans Carl Hasselbalch^{3

4}, Stig Egil Bojesen^{1

2

3}, Børge Grønne Nordestgaard^{1

2

3}

Affiliations

¹ Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
² The Copenhagen General Population Study, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
³ Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁴ Department of Haematology, Zealand University Hospital, Roskilde and Køge Hospital, Roskilde, Denmark.

No abstract available